

Market insights summary

North America aesthetic injectable market

What's trending and new

Hybrid fillers set the pace for North American market expansion

Hybrid fillers, combining hyaluronic acid with biostimulatory agents, are emerging
as a fast-growing category in North America, offering both immediate and long-term
results, potentially slowing HA filler volumes in the short-term but creating strong
opportunities for overall dermal filler market expansion.

Allergan remains a leader despite challenges in the aesthetics market

- Although Allergan parent company AbbVie has stated that it saw a decline in its
 aesthetics revenue in 2024 and early 2025, the company continues to prioritize
 innovation in aesthetics, with a focus on next-generation fillers like HArmonyCa and
 expanding indications for existing products, reinforcing its position as a key player.
- Due to growing competition in the dermal filler market, Allergan will need to continue to innovate, revise pricing to counter the shift toward less costly alternatives, as well as optimize inventory in response to economic and consumer behavior changes.

The increased uptake of GLP-1 agonists in North America will boost demand for complementary procedures like aesthetic injectable treatments.

• The widespread use of glucagon-like peptide-1 receptor agonists (GLP-1s) in North America is driving increased demand for injectables and skin-tightening treatments because rapid weight loss leads to facial volume loss and skin laxity.

Access more insights and data in the <u>report</u>.

<u>Speak to our team</u> to see how we can power your innovation.


2024 North America aesthetic injectable market snapshot

\$4.1B


Market revenue

7.6% CAGR ('19-'34)


North America aesthetic injectable market



North America BTX and dermal filler markets, 2024




Procedure growth by product type



BTX = Botulinum toxin HA = Hyaluronic acid

2024 North America aesthetic injectable competitive landscape



© 2025 Clarivate. All rights reserved.